In this study, stem cell therapy is compared with multiple effective MS treatments (alemtuzumab, cladribine or ocrelizumab). In the next two years, ten people with MS will undergo stem cell treatment at Amsterdam UMC. Stem cell therapy is currently neither reimbursed nor performed for MS in the Netherlands. To obtain reimbursement for stem cell therapy in the Netherlands, scientific research is needed in which the effectiveness and safety of stem cell therapy is directly compared with effective treatments for MS.
For a dutch version of this news item see: https://www.vumc.nl/nieuws/nieuwsdetail/studie-stamceltherapie-bij-ms-in-nederland-van-start-1.htm
For Q&A and patient recruitment: www.vumc.nl/stamceltherapiems